Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520157 | 1.00 | HTR6 (0.36) | HTR6QRFPRHTR1ASLC6A4HTR7 | |
| SCHEMBL4508664 | 0.82 | SLC22A12 (0.40) | HTR6QRFPRALPL | |
| SCHEMBL4518652 | 0.81 | HTR6 (0.50) | HTR6QRFPR | |
| SCHEMBL4529750 | 0.80 | PKM (0.38) | HTR6QRFPRALPL | |
| SCHEMBL4522186 | 0.79 | SLC22A12 (0.44) | HTR6QRFPRALPL | |
| SCHEMBL4521563 | 0.78 | MTNR1A (0.36) | — | |
| SCHEMBL4504853 | 0.69 | HTR6 (0.53) | HTR6QRFPRHTR7ALPL | |
| SCHEMBL4513876 | 0.69 | HTR6 (0.51) | HTR6QRFPR | |
| SCHEMBL4966066 | 0.69 | HTR6 (0.51) | HTR6QRFPR | |
| SCHEMBL4514124 | 0.69 | HTR6 (0.46) | HTR6QRFPRHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | HTR6 1/4885QRFPR 79/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.